XML 57 R42.htm IDEA: XBRL DOCUMENT
v3.20.4

Interim Consolidated Financial Information (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Interim Consolidated Financial Information (Unaudited) |
Schedule of Interim Consolidated Financial Information | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal 2020 Quarter Ended | ​
(in thousands, except per share data) |  | March 31, |  | June 30, |  | September 30, |  | December 31, | ​
Revenues(1) | ​ | $ | 568,507 | ​ | $ | 688,043 | ​ | $ | 620,643 |  | $ | 789,509 | ​
Net income (loss) | ​ | $ | (720,642) | ​ | $ | 290,298 | ​ | $ | (15,203) |  | $ | 149,850 | ​
Basic net income (loss) per share | ​ | $ | (3.33) | ​ | $ | 1.33 | ​ | $ | (0.07) | ​ | $ | 0.68 | ​
Diluted net income (loss) per share | ​ | $ | (3.33) | ​ | $ | 1.32 | ​ | $ | (0.07) | ​ | $ | 0.68 | ​
Shares used in computation of basic net income (loss) per share | ​ |  | 216,721 | ​ |  | 217,549 | ​ |  | 218,784 |  | ​ | 219,239 | ​
Shares used in computation of diluted net income (loss) per share | ​ | ​ | 216,721 | ​ | ​ | 220,434 | ​ | ​ | 218,784 | ​ | ​ | 221,228 | ​
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Fiscal 2019 Quarter Ended | ​
(in thousands, except per share data) |  | March 31, |  | June 30, |  | September 30, |  | December 31, | ​
Revenues(2) | ​ | $ | 497,857 | ​ | $ | 529,932 | ​ | $ | 551,581 |  | $ | 579,389 | ​
Net income | ​ | $ | 102,312 | ​ | $ | 105,318 | ​ | $ | 128,271 |  | $ | 111,005 | ​
Basic net income per share | ​ | $ | 0.48 | ​ | $ | 0.49 | ​ | $ | 0.60 | ​ | $ | 0.51 | ​
Diluted net income per share | ​ | $ | 0.47 | ​ | $ | 0.48 | ​ | $ | 0.59 | ​ | $ | 0.51 | ​
Shares used in computation of basic net income per share | ​ |  | 214,065 | ​ |  | 214,620 | ​ |  | 215,199 |  | ​ | 215,770 | ​
Shares used in computation of diluted net income per share | ​ | ​ | 217,061 | ​ | ​ | 217,483 | ​ | ​ | 217,791 | ​ | ​ | 218,542 | ​
(1) | The quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 include $486.7 million, $500.3 million, $522.3 million, and $559.5 million, respectively, of product revenues, net, relating to JAKAFI, ICLUSIG and PEMAZYRE. The quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 include $81.8 million, $92.8 million, $98.4 million and $119.9 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States and TABRECTA worldwide. The quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 include $0.0 million, $95.0 million, $0.0 million and $110.0 million, respectively, of milestone and contract revenues relating to the Innovent, Lilly and Novartis agreements.
(2) | The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $396.2 million, $433.9 million, $454.0 million, and $490.8 million, respectively, of product revenues, net, relating to JAKAFI and ICLUSIG. The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $61.6 million, $76.0 million, $80.1 million and $88.6 million, respectively, of product royalty revenues related to the sale of JAKAVI and OLUMIANT outside the United States. In December 2018 and July 2019, we entered into collaborative research and license agreements with Innovent and Zai Lab, respectively. The quarters ended March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019 include $40.0 million,
| $20.0 million, $17.5 million and $0.0 million, respectively, of milestone and contract revenues relating to these agreements.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration